Version One

versionone.vc

VCMatch tracks Version One as an investor focused on Digital Health, Biotech, and Medtech companies, Pre-Seed and Seed rounds, Global, North America, and Canada markets, and $500k to $1.5m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$500k to $1.5m

Stages

Pre-Seed, Seed

Focus Areas

Digital Health, Biotech, Medtech

Geography

global, North America, and Canada

Investment Thesis

Version One invests early in mission-driven founders building generational technology companies, with a particular emphasis on network effects and data-driven platforms. They believe technology can transform the world and that the Seed stage is where they can add the most value—providing fast decision-making, hands-on operational support, and follow-on capital to help founders find product-market fit, hire teams, and scale.

Is Version One right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Version One is most relevant for founders raising Pre-Seed and Seed rounds in Digital Health, Biotech, Medtech, and AI/ML, especially across global, North America, and Canada, with public check-size signals around $500k to $1.5m.

Focus statement

Seed-stage investments (they "typically lead or co-lead, with an investment of $500k - $1.5m") in bold founders building category-defining businesses—especially marketplaces, communities, social platforms and data/network-effect companies—and an increasingly deep focus on healthcare, genomics and biosciences (including clinical-grade/ FDA-pathway opportunities).

Value Add

Seed-specialist that "typically lead or co-lead, with an investment of $500k - $1.5m, and we often back our startups through multiple rounds."
Fast, founder-friendly process: "We strive for turnaround times of a few days (not weeks)" so founders can stay focused on building.
Operational empathy and mentorship: team has "run our own companies before" and aims to be "the first investor that founders call when they need advice."
Thesis-driven on network effects and data: "we like to invest in businesses with potentially large network effects built around people and/or data."
Geography-agnostic posture and emphasis on bridging unequal opportunity: "Generational companies aren’t limited by geographies" and "Talent and great ideas can exist anywhere—but opportunity is rarely distributed equally."
Willingness to back deeper technical/regulated healthcare plays (clinical-grade devices, FDA pathways) as part of a "full stack" data approach: "D2C (for rapid adoption) –> FDA clearance, approval –> gold standard –> cost structure change."